Prelude Therapeutics (PRLD) Cash & Equivalents (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Cash & Equivalents data on file, last reported at $84.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 91.37% year-over-year to $84.8 million; the trailing twelve-month figure through Mar 2026 stood at $84.8 million (up 91.37% YoY), and the FY2025 full-year result was $35.3 million, up 113.44% from the prior year.
• Cash & Equivalents advanced to $84.8 million in Q1 2026, from $35.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $84.8 million in Q1 2026 to a low of $15.2 million in Q3 2024.
• A 5-year average of $40.3 million and a median of $34.6 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 84.66% in 2022 and soared 213.16% in 2025, its largest moves.
• Tracing PRLD's Cash & Equivalents over 5 years: stood at $34.6 million in 2022, then fell by 15.34% to $29.3 million in 2023, then sank by 43.69% to $16.5 million in 2024, then jumped by 113.44% to $35.3 million in 2025, then jumped by 140.53% to $84.8 million in 2026.
• Business Quant data shows PRLD's Cash & Equivalents at $84.8 million in Q1 2026, $35.3 million in Q4 2025, and $47.5 million in Q3 2025.